Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Figure 3 | BMC Medicine

Figure 3

From: Increased deposition of C3b on red cells with low CR1 and CD55 in a malaria-endemic region of western Kenya: Implications for the development of severe anemia

Figure 3

Changes in %C3b-positive red cells, CR1, CD55, and hemoglobin according to malaria status. a. %C3b-positive red cells. Unadjusted ANOVA for the difference in %C3b-positive red cells across groups P(malaria-treated) = 2.5 × 10-11, P(aparasitemic) = 1.2 × 10-7. Independent samples t-test for the comparison between malaria-treated and aparasitemic individuals for the indicated age groups, *P = 0.04, P = 2.8 × 10-4, P = 0.09, P = 0.03. b. Red cell CD55. Unadjusted ANOVA for the difference in CD55 across groups, P(malaria-treated) = 0.01 and P(aparasitemic) = 0.05. ABC = Antibody binding capacity. c. Red cell CR1. Unadjusted ANOVA for the difference in CR1 across groups, P(malaria-treated) = 0.02 and P(aparasitemic) = 1.9 × 10-6. Independent samples t-test for the comparison between malaria-treated and aparasitemic individuals for the indicated age groups, *P = 0.01, P = 0.58, P = 0.09. d. Hemoglobin level. Unadjusted ANOVA for the difference in Hgb level across groups, P(malaria-treated) = 9.8 × 10-19, P(aparasitemic) = 3.8 × 10-20. Independent samples t-test for the comparison between malaria-treated and aparasitemic individuals for the indicated age groups, *P = 0.02, P = 0.05, P = 0.03, P = 0.11.

Back to article page